AU2012283858C1 - Polypeptide separation methods - Google Patents

Polypeptide separation methods Download PDF

Info

Publication number
AU2012283858C1
AU2012283858C1 AU2012283858A AU2012283858A AU2012283858C1 AU 2012283858 C1 AU2012283858 C1 AU 2012283858C1 AU 2012283858 A AU2012283858 A AU 2012283858A AU 2012283858 A AU2012283858 A AU 2012283858A AU 2012283858 C1 AU2012283858 C1 AU 2012283858C1
Authority
AU
Australia
Prior art keywords
receptor
polypeptide
medium
glycoform
gamma
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2012283858A
Other languages
English (en)
Other versions
AU2012283858B2 (en
AU2012283858A1 (en
Inventor
Austin Wayne Boesch
Glen Reed Bolton
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Zepteon Inc
Original Assignee
Zepteon Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=46634526&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AU2012283858(C1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Zepteon Inc filed Critical Zepteon Inc
Publication of AU2012283858A1 publication Critical patent/AU2012283858A1/en
Publication of AU2012283858B2 publication Critical patent/AU2012283858B2/en
Application granted granted Critical
Publication of AU2012283858C1 publication Critical patent/AU2012283858C1/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • C07K1/22—Affinity chromatography or related techniques based upon selective absorption processes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C12P21/005—Glycopeptides, glycoproteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2440/00—Post-translational modifications [PTMs] in chemical analysis of biological material
    • G01N2440/38—Post-translational modifications [PTMs] in chemical analysis of biological material addition of carbohydrates, e.g. glycosylation, glycation

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Analytical Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
AU2012283858A 2011-07-20 2012-07-20 Polypeptide separation methods Ceased AU2012283858C1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161509746P 2011-07-20 2011-07-20
US61/509,746 2011-07-20
PCT/US2012/047699 WO2013013193A1 (en) 2011-07-20 2012-07-20 Polypeptide separation methods

Publications (3)

Publication Number Publication Date
AU2012283858A1 AU2012283858A1 (en) 2014-03-06
AU2012283858B2 AU2012283858B2 (en) 2017-07-06
AU2012283858C1 true AU2012283858C1 (en) 2020-01-23

Family

ID=46634526

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2012283858A Ceased AU2012283858C1 (en) 2011-07-20 2012-07-20 Polypeptide separation methods

Country Status (11)

Country Link
US (2) US10221210B2 (enExample)
EP (1) EP2734537B1 (enExample)
JP (1) JP2014527518A (enExample)
KR (1) KR20140062469A (enExample)
CN (1) CN103827134A (enExample)
AU (1) AU2012283858C1 (enExample)
BR (1) BR112014001120A2 (enExample)
CA (1) CA2842559A1 (enExample)
IL (1) IL230486A0 (enExample)
WO (1) WO2013013193A1 (enExample)
ZA (1) ZA201401140B (enExample)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103827134A (zh) 2011-07-20 2014-05-28 泽普泰恩股份有限公司 多肽分离方法
KR20140077178A (ko) * 2011-10-19 2014-06-23 로슈 글리카트 아게 푸코실화 항체의 분리 방법
KR102069397B1 (ko) 2012-02-15 2020-01-22 에프. 호프만-라 로슈 아게 Ｆｃ-수용체 기재 친화성 크로마토그래피
WO2014145744A1 (en) * 2013-03-15 2014-09-18 Alder Biopharmaceuticals, Inc. Antibody purification and purity monitoring
CN105555801B (zh) * 2013-09-18 2020-05-05 东曹株式会社 Fc结合性蛋白质、该蛋白质的制造方法和使用了该蛋白质的抗体吸附剂、以及使用了该吸附剂的抗体的纯化方法及识别方法
FR3025515B1 (fr) * 2014-09-05 2016-09-09 Lab Francais Du Fractionnement Procede de purification d'un anticorps monoclonal
PT3215528T (pt) 2014-11-06 2019-10-11 Hoffmann La Roche Variantes da região fc com ligação modificada ao fcrn e métodos de utilização
US20180319838A1 (en) * 2015-11-04 2018-11-08 Biogen Ma Inc. Conjugation methods for modifying or immobilizing proteins
US10738338B2 (en) 2016-10-18 2020-08-11 The Research Foundation for the State University Method and composition for biocatalytic protein-oligonucleotide conjugation and protein-oligonucleotide conjugate
EP3824906A1 (en) 2016-12-21 2021-05-26 Amgen Inc. Anti-tnf alpha antibody formulations
JP7047425B2 (ja) * 2017-02-20 2022-04-05 東ソー株式会社 抗体の分離能が向上したＦｃ結合性タンパク質およびそれを用いた抗体の分離方法
US11603548B2 (en) 2017-10-27 2023-03-14 Tosoh Corporation Fc-binding protein exhibiting improved alkaline resistance, method for producing said protein, antibody adsorbent using said protein, and method for separating antibody using said antibody adsorbent
WO2020086893A1 (en) 2018-10-25 2020-04-30 Regeneron Pharmaceuticals, Inc. Methods for analysis of viral capsid protein composition
CN114096560B (zh) * 2019-07-03 2025-06-13 默克专利股份公司 糖型纯化
ES3031876T3 (en) * 2021-02-09 2025-07-11 Genequantum Healthcare Suzhou Co Ltd Conjugation device and method for producing conjugates

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1333032A1 (en) * 2000-10-06 2003-08-06 Kyowa Hakko Kogyo Co., Ltd. Method of purifying antibody
US20030175969A1 (en) * 2000-04-12 2003-09-18 Roland Beliard Anti-rhesus d monoclonal antibodies
WO2010048313A2 (en) * 2008-10-22 2010-04-29 Biogen Idec Ma Inc. Recombinant fcrn and variants thereof for purification of fc-containing fusion proteins

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3932557A (en) 1972-12-19 1976-01-13 Gulf Research & Development Company Reactive hydrophilic epoxy containing polymer
US4210723A (en) 1976-07-23 1980-07-01 The Dow Chemical Company Method of coupling a protein to an epoxylated latex
DE3543348A1 (de) 1985-12-07 1987-06-11 Bayer Ag Perlfoermige vernetzte, epoxy- und basische aminogruppen aufweisende mischpolymerisate, verfahren zu ihrer herstellung und ihre verwendung
US5260373A (en) 1987-03-13 1993-11-09 Repligen Corporation Immobilized immunoglobulin-binding proteins
GB8902770D0 (en) 1989-02-08 1989-03-30 Bioprocessing Ltd Improvements in or relating to supports for immunoaffinity separations
SE467308B (sv) 1990-10-22 1992-06-29 Berol Nobel Ab Fast yta belagd med ett hydrofilt ytterskikt med kovalent bundna biopolymerer, saett att framstaella en saadan yta och ett konjugat daerfoer
US5456909A (en) * 1992-08-07 1995-10-10 T Cell Sciences, Inc. Glycoform fractions of recombinant soluble complement receptor 1 (sCR1) having extended half-lives in vivo
US5543054A (en) 1993-11-24 1996-08-06 Millipore Corporation Method and apparatus for covalent immobilization of charge- conjugated carbohydrate molecules
SE9503925D0 (sv) 1995-11-07 1995-11-07 Pharmacia Biotech Ab Separationsmedium för IgG
US5874165A (en) 1996-06-03 1999-02-23 Gore Enterprise Holdings, Inc. Materials and method for the immobilization of bioactive species onto polymeric subtrates
CA2307166A1 (en) * 1997-10-31 1999-05-14 Genentech, Inc. Methods and compositions comprising glycoprotein glycoforms
EP1006183A1 (en) 1998-12-03 2000-06-07 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Recombinant soluble Fc receptors
US7029872B2 (en) 2000-06-28 2006-04-18 Glycofi, Inc Methods for producing modified glycoproteins
US7449308B2 (en) 2000-06-28 2008-11-11 Glycofi, Inc. Combinatorial DNA library for producing modified N-glycans in lower eukaryotes
US7625756B2 (en) 2000-06-28 2009-12-01 GycoFi, Inc. Expression of class 2 mannosidase and class III mannosidase in lower eukaryotic cells
US7598055B2 (en) 2000-06-28 2009-10-06 Glycofi, Inc. N-acetylglucosaminyltransferase III expression in lower eukaryotes
PL213948B1 (pl) 2001-10-25 2013-05-31 Genentech Inc Kompozycje zawierajace glikoproteine, czasteczka kwasu nukleinowego kodujaca te glikoproteine, komórka gospodarza, sposób wytwarzania glikoproteiny, kompozycja do zastosowania do leczenia, zastosowanie kompozycji i zestaw zawierajacy kompozycje
ITMI20020729A1 (it) 2002-04-08 2003-10-08 Resindion S R L Supporti per l'immobilizzazione covalente di enzimi
US7261893B2 (en) 2002-10-22 2007-08-28 Wyeth Neutralizing antibodies against GDF-8 and uses therefor
ES2214136B1 (es) 2003-02-21 2007-05-16 Consejo Sup. De Invest. Cientificas. Nuevo metodo de inmovilizacion de enzimas y otras bio-macromoleculas sobre soportes activados con grupos epoxido conteniendo grupos ionizados en el brazo espaciador que une cada grupo epoxido a la superficie del soporte.
JP2007535317A (ja) 2004-04-15 2007-12-06 グライコフィ， インコーポレイテッド 下等真核生物におけるガラクトシル化された糖タンパク質の産生
JP4839583B2 (ja) 2004-07-15 2011-12-21 和光純薬工業株式会社 ＦｃγレセプターＩＩＩａに特異的な抗体およびそれを用いたＦｃγレセプターＩＩＩａの測定方法
US20080312425A1 (en) * 2004-08-30 2008-12-18 Lonza Biologics Plc. Ion Exchange Chromatography and Purification of Antibodies
ES2396555T3 (es) 2004-12-15 2013-02-22 Janssen Alzheimer Immunotherapy Anticuerpos que reconocen péptido beta amiloide
BRPI0608584B8 (pt) 2005-03-11 2021-05-25 Wyeth Corp métodos de recuperar um produto purificado
BRPI0611600B8 (pt) * 2005-06-17 2021-05-25 Wyeth Corp método para purificação de uma proteína tendo uma região fc a partir de um líquido fonte compreendendo a proteína e uma ou mais impurezas, e kit
ES2642787T3 (es) 2005-10-21 2017-11-20 Lfb Usa, Inc. Anticuerpos con actividad de citotoxicidad celular dependiente de anticuerpos mejorada, métodos para su producción y uso
JP5530633B2 (ja) * 2006-01-06 2014-06-25 イー・エム・デイー・ミリポア・コーポレイシヨン アフィニティークロマトグラフィーマトリックスおよびその作成および使用法。
DK2041270T3 (da) 2006-07-13 2014-01-27 Wyeth Llc Fremstilling af glycoproteiner
US8969532B2 (en) 2006-10-03 2015-03-03 Novo Nordisk A/S Methods for the purification of polypeptide conjugates comprising polyalkylene oxide using hydrophobic interaction chromatography
WO2008085988A1 (en) * 2007-01-05 2008-07-17 Amgen Inc. Methods of purifying proteins
US20080248510A1 (en) 2007-04-03 2008-10-09 Ulrich Brinkmann HUMAN Fc GAMMA RECEPTOR III
EP2136896B1 (en) 2007-04-16 2015-01-21 Momenta Pharmaceuticals, Inc. Multi-dimensional chromatographic methods for separating n-glycans
AU2008275649B2 (en) 2007-07-12 2013-09-05 Sangamo Therapeutics, Inc. Methods and compositions for inactivating alpha 1,6 fucosyltransferase (FUT 8) gene expression
US20090035807A1 (en) 2007-07-31 2009-02-05 Wyeth Analysis of polypeptide production
US20110117601A1 (en) * 2007-08-31 2011-05-19 Markus Haberger Glycosylation Profile Analysis
JP2010126436A (ja) * 2008-11-25 2010-06-10 Tosoh Corp 抗体精製用吸着剤、およびそれを用いた抗体精製方法
US8536316B2 (en) * 2009-08-07 2013-09-17 Emd Millipore Corporation Methods for purifying a target protein from one or more impurities in a sample
CN103827134A (zh) 2011-07-20 2014-05-28 泽普泰恩股份有限公司 多肽分离方法
KR20140077178A (ko) 2011-10-19 2014-06-23 로슈 글리카트 아게 푸코실화 항체의 분리 방법

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030175969A1 (en) * 2000-04-12 2003-09-18 Roland Beliard Anti-rhesus d monoclonal antibodies
EP1333032A1 (en) * 2000-10-06 2003-08-06 Kyowa Hakko Kogyo Co., Ltd. Method of purifying antibody
WO2010048313A2 (en) * 2008-10-22 2010-04-29 Biogen Idec Ma Inc. Recombinant fcrn and variants thereof for purification of fc-containing fusion proteins

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
Bruhns et al., Blood 113, pages 3716-25 (2009) *
Lida et al., Clin Cancer Res, 12(9), pages 2879-87, 1 May 2006 *
Okazaki et al, J. Mol. Biol., 336, pages 1239-49 (2004) *
Shields et al, Journal of Biological Chemistry, 277, pages 26733-740 (2002) *
Tojo et al., Biol. Pharm. Bull. 32(9), pages 1604-08 (2009) *

Also Published As

Publication number Publication date
ZA201401140B (en) 2015-04-29
AU2012283858B2 (en) 2017-07-06
BR112014001120A2 (pt) 2017-02-21
JP2014527518A (ja) 2014-10-16
KR20140062469A (ko) 2014-05-23
US10221210B2 (en) 2019-03-05
CA2842559A1 (en) 2013-01-24
WO2013013193A1 (en) 2013-01-24
EP2734537A1 (en) 2014-05-28
US20190194248A1 (en) 2019-06-27
IL230486A0 (en) 2014-03-31
EP2734537B1 (en) 2022-12-21
AU2012283858A1 (en) 2014-03-06
US20130084648A1 (en) 2013-04-04
CN103827134A (zh) 2014-05-28

Similar Documents

Publication Publication Date Title
AU2012283858B2 (en) Polypeptide separation methods
DK2729482T3 (en) PROCEDURE FOR CLEANING FC-FUSION PROTEIN
EP3048899B1 (en) On-column viral inactivation methods
RU2624128C2 (ru) Аффинная хроматография с применением fc-рецепторов
US10533045B2 (en) Antibody purification and purity monitoring
KR102490956B1 (ko) 불순물을 제거하기 위한 크로마토그래피 동안의 알칼리성 세척의 용도
CN107163101B (zh) 超载和洗脱层析
KR101454316B1 (ko) 활성형 ＴＮＦＲ-Ｆｃ 융합 단백질을 제조하는 방법
CN110100007B (zh) 用于体外糖工程化抗体的酶的再使用
KR20150138273A (ko) 단백질의 피로­글루타민산 형성을 증가시키기 위한 방법
CN117887794A (zh) 用于体外糖工程化抗体的方法
CA2974033A1 (en) Anti-glycoprotein antibodies and uses thereof
RU2698671C2 (ru) КОЛИЧЕСТВЕННАЯ ОЦЕНКА НЕПРАВИЛЬНО СВЕРНУТОГО TNFR2:Fc
JP2016504337A (ja) イオン交換クロマトグラフィーを使用して高マンノースグリコフォームのレベルを制御する方法
HK40062819A (en) On-column viral inactivation methods
HK40042659A (en) Antibody purification and purity monitoring
HK40011892A (en) Re-use of enzymes in in vitro glycoengineering of antibodies
HK40011888A (en) Method for in vitro glycoengineering of antibodies
HK40011889A (en) In vitro glycoengineering of antibodies
HK40011892B (en) Re-use of enzymes in in vitro glycoengineering of antibodies

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
DA2 Applications for amendment section 104

Free format text: THE NATURE OF THE AMENDMENT IS AS SHOWN IN THE STATEMENT(S) FILED 08 FEB 2019

CB4 Opposition filed under section 104(4)

Opponent name: PIZZEYS PATENT AND TRADE MARK ATTORNEYS PTY LTD

CC Opposition dismissed

Opponent name: PIZZEYS PATENT AND TRADE MARK ATTORNEYS PTY LTD

DA3 Amendments made section 104

Free format text: THE NATURE OF THE AMENDMENT IS AS SHOWN IN THE STATEMENT FILED 08 FEB 2019

MK14 Patent ceased section 143(a) (annual fees not paid) or expired